Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Meperidine price, strengths & recalls

Pharmacies pay $78.36 for 500 mL of Meperidine 10 mg/mL oral solution this week. 2 manufacturers make it. It is in shortage (in shortage). It has 4 recalls on record, none ongoing. Its official label last changed on February 18, 2026.

In shortageGeneric
Pharmacies pay$78.36for 500 mL of 10 mg/mL oral solutionNo change in 4 weeks
Fair cash price
$100.61
Strengths
1
Makers
2
Updated
Nov 11

Meperidine price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
10 mg/mL oral solution$0.1567$78.36 / 500 mLNo change+2.0%
50 mg tabletNot priced this week

Supply status: shortages & recalls

In shortage6 products are short or being discontinued
No ongoing recalls4 recalls on record, latest Feb 28, 2018

Shortages

  • Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)Hikma Pharmaceuticals USA, Inc. · Available · Updated Oct 14, 2026Additional lots are scheduled to be manufactured. Product will be made available as it is released.
  • Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)Hikma Pharmaceuticals USA, Inc. · Available · Updated Oct 14, 2026Additional lots are scheduled to be manufactured. Product will be made available as it is released.
  • Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)Hikma Pharmaceuticals USA, Inc. · Available · Updated Oct 14, 2026Additional lots are scheduled to be manufactured. Product will be made available as it is released.

In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for meperidine? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedFebruary 18, 2026
Version2 of 2
EffectiveFeb 13, 2026
Read the label

These highlights do not include all the information needed to use MEPERIDINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEPERIDINE HYDROCHLORIDE TABLETS. MEPERIDINE HYDROCHLORIDE TABLETS, for oral use, CII Initial U.S. Approval: 1942

This drug has a boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MEPERIDINE HYDROCHLORIDE TABLETS

Addiction, Abuse, and Misuse

Because the use of Meperidine hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.2)].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of Meperidine hydrochloride tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of meperidine hydrochloride tablets are essential [see Warnings and Precautions (5.3)].

Accidental Ingestion

Accidental ingestion of Meperidine hydrochloride tablets, especially by children, can result in a fatal overdose of meperidine [see Warnings and Precautions (5.3)].

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of Meperidine Hydrochloride Tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.4), Drug Interactions (7)].

Neonatal Opioid Withdrawal Syndrome (NOWS)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.5)].

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.6)].

Cytochrome P450 3A4 (CYP3A4) Interaction

The concomitant use of meperidine hydrochloride tablets with all cytochrome P450 3A4 (CYP3A4) inhibitors may result in an increase in meperidine plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used CYP 3A4 inducer may result in an increase in meperidine plasma concentration. Frequently reevaluate patients receiving meperidine hydrochloride tablets and any CYP 3A4 inhibitor or inducer [see Warnings and Precautions (5.7), Drug Interactions (7)].

Monoamine Oxidase Inhibitors (MAOIs) Interaction

Concomitant use of meperidine hydrochloride tablets with monoamine oxidase inhibitors (MAOIs) can result in coma, severe respiratory depression, cyanosis, and hypotension. Use of meperidine hydrochloride tablets with MAOIs within the last 14 days is contraindicated [see Contraindications (4), Warnings and Precautions (5.8), Drug Interactions (7)].

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MEPERIDINE HYDROCHLORIDE TABLETS

See full prescribing information for complete boxed warning.

Meperidine hydrochloride tablets expose users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. (5.2)

Serious, life-threatening, or fatal respiratory depression may occur, especially upon initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of meperidine hydrochloride tablets are essential. (5.3)

Accidental ingestion of meperidine hydrochloride tablets, especially by children, can result in a fatal overdose of meperidine. (5.3)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.4, 7)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. (5.5)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (5.6)

Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in fatal overdose of meperidine (5.7, 7)

Concomitant use of meperidine hydrochloride tablets with monoamine oxidase inhibitors (MAOIs) can result in coma, severe respiratory depression, cyanosis and hypotension. Use of meperidine hydrochloride tablets with MAOIs within the last 14 days is contraindicated. (4, 5.8, 6)

Recent major changes (as listed on the label)

Boxed Warning | 12/2025 |

Indications and Usage (1) | 12/2025 |

Dosage and Administration (2.2, 2.6) | 12/2025 |

Warnings and Precautions (5.2, 5.3, 5.4, 5.15, 5.17) | 12/2025 |

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Generic makers
2 approved generic applications on the market

Meperidine questions

How much does meperidine cost without insurance?

Pharmacies pay about $78.36 for 500 mL of meperidine 10 mg/mL oral solution ($0.1567 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $100.61. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is meperidine in shortage?

Yes. 6 products are listed as in shortage or being discontinued (in shortage). See which ones.

Has meperidine been recalled?

4 recalls on record, none ongoing. Recalls name specific lots - check yours.

When did the meperidine label last change?

The official label was last updated on February 18, 2026 (version 2). See what changed.

Talk about meperidine

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.